Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03185650 · ClinicalTrials.gov registry record · NA

Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device

A NA study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT03185650 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03185650, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

Purpose: Characterize the depositional attributes of a specialized trans-nasal aerosol delivery device in healthy people using clinical measurements of mucociliary clearance. Procedures (methods): 14% hypertonic saline (HS) aerosol containing the radio tracer Tc99m-sulfur colloid will be delivered via the tPAD and compared to the well characterized PARI LC Star nebulizer (7% HS) using planar gamma scintigraphy (i.e. particle clearance). The fraction of sulfur colloid particles that clear over the ensuing 24 hours with each device will indicate the fraction deposited in conducting airways.

Interventions

  • DEVICE tPAD Device
  • DEVICE PARI LC Star Nebulizer

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-07-27
Est. Completion 2018-07-27
Phase NA

What the Registry Record Tells You About NCT03185650

The ClinicalTrials.gov registry entry for NCT03185650 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which tPAD Device is the first listed.

NCT03185650 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03185650 about?

NCT03185650 is a clinical study titled "Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device". Purpose: Characterize the depositional attributes of a specialized trans-nasal aerosol delivery device in healthy people using clinical measurements of mucociliary clearance. Procedures (methods): 14% hypertonic saline (HS) aerosol containing the radio tracer Tc99m-sulfur colloid will be delivered ...

What is the current status of trial NCT03185650?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-07-27. Estimated completion is 2018-07-27.

What interventions are being tested in trial NCT03185650?

The interventions under investigation include: tPAD Device (DEVICE), PARI LC Star Nebulizer (DEVICE).

Who is sponsoring clinical trial NCT03185650?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.